. The main goal of the JFWP is to facilitate the rapid progress of a new drug through pharmaceutical developmental to preclinical toxicology and subsequently to phase I clinical trial. Under the auspices of the JFWP around 50 new agents have been developed or are currently in development. In this report we present our formulation experienc since the establishment of the JFWP with a seklcted number of agents: aphidicolin glycinate, bryostatin 1, carmethizole, carzelesin, combretastatin A4, dabis maleate, disulphonated aluminium phthalocyanine, E.O.9, 4-hydroxyanisole, pancratistatin, rhizoxin, Springer pro-drug, SRI 62-834, temozolomide, trimelamol and V489. The approaches used and problems presented may be of general interest to scientists in related fields and those considering submitting agents for development.
Anti-tumour agents represent a unique pharmacological group since they are chemically variable and initial human phase I clinical trials are conducted not in volunteers but in patients. Additionally, it is important to determine rapidly if any new agent arising from current research may represent an advance on contemporary therapy. The bridge between in vitro agent and useful medicine is crossed by the application of pharmaceutical techniques to produce a product that embodies the principles of safety, quality and efficacy. However, the pharmaceutical formulation of a new antineoplastic agent involves a variety of stages and has often been perceived as a bottleneck in drug development because of the time required.
The formulation process necessitates a thorough identification and characterisation of the raw material, including determination of physicochemical properties such as stability and solubility. A formulation (normally parenteral) is then developed, its suitability assessed and appropriate manufacturing methods determined (see Vezin and Salole, 1993 , for a full exposition of this process). The formulated products are then subjected to preclinical toxicology studies and subsequently clinical trials; throughout this process a number of hurdles may arise which can delay or block development.
In 1987 the Cancer Research Campaign (CRC), the European Organization for Research and Treatment of Cancer (EORTC) and the National Cancer Institute (NCI) agreed to form the Joint Formulation Working Party (JFWP) in which formulation scientists collaborate in the pharmaceutical development of investigational anti-cancer drugs. The JFWP ensures international continuity and through application of quality control, good laboratory practice (GLP) and good manufacturing practice (GMP), high quality standards during pharmaceutical development. In 1988 the JFWP pubhshed formulation guidelines for investigational cytotoxic drugs (Davignon et al., 1988) which have contributed to a more standardised approach to pharmaceutical development in Europe and the United States. This standardisation of formulation design should aid in the transfer of technology, allowing simultaneous drug development in several countries.
In this paper we describe a selection of investigational agents that were developed under JFWP auspices and which are now at different developmental stages. The cases presented significant formulation challenges, and to categorise these examples they have been grouped under four headings: analytical, solubility, stability and excipient problems. It should be noted, however, that several compounds presented challenges in all areas! Many of the problems have been resolved with unique approaches which may be beneficial in related scientific fields; unfortunately, in some cases, an answer has yet to be found and development is currently stymied.
All research processes require a suitable specific and interference-free analytical technique to measure the compound under test. To ensure assay integrity therefore requires consumption of material through induced breakdown to produce possible interfering degradation products. Since the majority of these experimental compounds are in short supply, assay development can be restricted but is still necessary to produce a validated assay. The majority of drugs contain chromophores, therefore simple spectrophotometric techniques may be applied; occasionally unusual approaches may have to be adopted because of the compound's chemical properties. outset bryostatin 1 was in extremely short supply, with only 20 mg available, stability and preformulation work was conducted using a small proportion of this sample. Additional probkms were presented by the compound's high potency and attendant toxicological implications; the estimated starting dose was around 5 1zg m-2. However, the techniques adopted to ensure minimal drug losses during transference also minimised the risk of accidental exposure.
The lack of available material precluded a complete solubility investigation in a range of pharmaceutically acceptable solvents. Formulation was based on data from the drug's discoverers, which demonstrated bryostatin's lmited aqueous solubility (Pettit et al., 1982) ; ethanol was therefore chosen as a prospective solvent. The solubility of ethanolic solutions was investigated using modified protocols to keep the volumes used as low as possible. At predicted formulation concentrations the drug precipitated when the percentage of ethanol fell below 50%. These experiments were conducted on the assumption that the eventual formulation should be capable of in-line filtration through a 0.22 iM filter during administration. In the phase I dinical trial the ethanol solution was diluted well below 50% in an attempt to reduce phlebitis, thought to be associated with the high ethanol concentration. No in-lne filter was used and there were no reported problems with emboli caused by precipitated drug.
The use of administration sets with such low drug doses and concentrations necessitated that compatibility and adsorption studies be conducted using appropriate plastics. It was found that if polytetrafluorethylene (PITFE)-lined plastic was not used (e.g. polyvinylchloride, PVC) there was extensive adsorption onto administration set surfaces. The adsorption was also significant with FIFE-lined sets when the ethanol concentration fell below 50%. The phlebitis was clinically addressed using in-line dilution with saline. There was initial concern when it was suggested that the total dose may not be delivered owing to precipitation or adsorption. However, later in the trial the major toxicity was a general myalgia present whether or not the drug was subject to in-line dilution, suggesting that a significant amount of bryostatin was being delivered.
During preclinical toxicology studies, there were major investments in the isolation and purification of > 10 g quantities of bryostatin 1, which permitted the development of a more acceptable lyophilised formulation from a 50:50 tbutanol-water solution containing polyvinylpyrrolidone (bulking agent). The lyophilised product is reconstituted with polyethylene glycol 400-ethanol-polysorbate 80 (60:3010, v/v/v) and then further diluted with saline before administration (Flora et al., 1993 Figure 2 ) (Tagliabue et al., 1992) is an example of a drug whose pharmaceutical development was delayed owing to inadequate analytical methodology. The molecule is the dimaleate salt of 1,4-bis(2'-chloroethyl)-l,4-diazabicyclo[2.2.1Jhptane. It contains two quaternary nitrogens but lacks a chromophore that could be used for ultraviolet (UV) detection following high-performance liquid chromatographic (HPLC) separation. This analytical problem was solved by the use of a 1i-Bondapak phenyl column using a mobile phase containing naphthalene sulphonic acid as an ion-pair reagent. The naphthalene sulphonic acid provided an indirect visuasation reagent since the drug-ion pair had a reduced UV adsorption at 260 nm and could be seen as a negative peak eluting from the column. This method also had the advantage of being able to quantify the malekic acid. The developed methodology enabled the preformulation and stability studies to be conducted in the normal way. In phase I studies using an administration schedule of once every 3 weeks the doselmiting toxicity was neurotoxicity and the recommended dose for phase II trials was 750 mg m-2 (van der Burg et al., 1991). Prolonged infusion resulted in neurotoxicity consisting of parasthesia and ataxia, with a recommended phase H dose of 500 mg m2 week-' as a 6 h infusion for 6 weeks followed by a 3 week drug vacation (Verweij et al., 1992 (Waud et al., 1992) . Formulation-rdated studies on the stability and mhanism of decomposition of carmethizole hydrochloride have been described (Stella et al., 1991 
Pancratistatin
Pancratistatin (NSC-349156, Figure 9 ) possesses anti-cancer and antiviral activity (Gabrielsen et al., 1992) but is poorly solube Iess than 0.4 mg ml-') in a range of solvents [aqueous, alcoholic, aqueous dimethylsulphoxide (DMSO), dimethylformamide (DMF) and DMA]. The aqueous solubility is signifiantly enhanced by nicotinamide at 150mgml-', which acts as a complexing agent providing pancratistatin solubilisation to 1 mg ml-'. Lyophilisation in the presence of nicotinamide resulted in cakes which were readily reconstituted in water to provide solutions with a pH value of 6.3. The lyophilised product (5 mg of drug and 600 or 800 mg of nicotinamide per vial) was satisfactory in appearance, however after storage at room temperature for 2 months reconstitution was problematical. Feasibility studie for a liquid formulation were also conducted, but the solution became light yellow in colour and further darkening occurred with ageing. The development of colour was effectively inhibited by the addition of a chelating agent (1% EDTA) and the use of nitrogen atmosphere. In contrast, the antioxidant sodium bisulphite greatly enhanc colour development during storage. Unfortunately, the anticipated clinical doses of pancratistatin are relatively high, which would require the administration of unacceptably high levels of nicotinamide. Alternative formulations based on the microsuspension method of Violante (Sands et al., 1987) were unsuccessful. Recently, the ability of hydroxypropyl-pcyclextrin (HPCD) to enhance the solubility of pancratistatin was evaluated. A 40% aqueous solution of HPCD was found to solubilise approximately 1.2 mg ml-' of drug (Torres-Labandeira et al., 1991) . This level of solubility is, however, not sufficient for clinical use, and at present development is on hold awaiting the synthesis of prodrugs.
Rhizoxin
Rhizoxin (NSC-332598, Figure 10 ) is a 16-membered antifimgal macrocycic lactone isolated from the plant pathogenic fungus Rlzizopus chnensis (Iwasaki et al., 1984) . It has potent antifungal as well as cytotoxic activity. Chemically it is unstable and is an example of a new cytotoxic drug with very poor water solubility (12 jig ml-'). For initial studies it was necessary to develop a parenteral dosage form of rhizoxin containing 1 mg ml-'. In order to obtain the desire stabilty and concentration, a number of solubility and stability characteristics were examined. Since rhizoxin has no ionisable groups and has poor water solubility, the only route capable of achieving the desired solubility, other than chemical modification, is the use of complexation, micellar solubilisation or co-solvents. Complexation was ruled out because of the 100-fold increase in solubility that would be required and micellar solubilisation, since cremophors have been associated with incidences of anaphylaxis. Success was achieved by using a co-solvent system containing 40% propylene glycol-10% ethanol-water, and stability studies revealed that the maximum stability occurred at pH 5.6 ± 0.1. Degradation products observed at acidic pH values are probably the result of acid-catalysed cleavage of the lactone ring(s) and/or both of the epoxide rings, while alkaline treatment most probably produces a carboxylic acid, resulting from cleavage of rhizoxin's larger lactone ring. The first-order kietics of degradation in vanous alcoholic solvents demonstrated that rhizoxin is signintly more stable in alcohol than in purely aqueous systems. As powdered rhizoxin is subject to photochemical degradation, experiments were performed to examine its behaviour in the presence and absence of light. In aqueous and alcoholic solutions, especially at acidic and alkalie pH, the degradation kinetics did not appear to be particularly sensitive to light. In contrast, at pH 5.6 in presence of light there was an approximately 2-fold increase in degradation compared with solutions protected from light. This data indicated that rhizoxin was not suitable for formulation as a ready-made aqueous or alcoholic solution and the very poor water solubility prohibited freeze drying from aqueous solutions. The solubility in t-butanol and t-butanol-water mixtures was, however, excellent, and these solvents, which are also used in other pharmaceutical preparations, could therefore be used to prepare freeze-dried samples of rhizoxin (Stella et al., 1988) . Excellent freeze-dried cakes were prepared from a 40% t-butanol-water mixture using mannitol as a bulking agent. The freeze-dried formulation containing 5 mg of rhizoxin could be reconstituted with 5 ml of the sterile solvent 40% propylene glycol-10/% ethanol-water to give a rhizoxin concentration of 1 mg ml-'. Interestingly, decomposition product analysis from freeze-dried samples did not produce the same pattern as noted during the hydrolytic studies. Oxidative breakdown was suspected because of the extended conjugated double-bond system, a theory supported by the fact that ascorbic acid signiinty enhanced the solid state stability. chemically and physically stable for 3 months, but after this time emulsion breakdown is evident with creaming at 20-C and coalscence at 50'C. Assay for drug content, however, reveals that little chemical degradation has taken place even at the higher temperatures. Because of the physical instability of this agent in solution a useful formulation has yet to be developed. Although in vitro results have been intresting, further development is unlkely since only the racemic form is available.
Trimelawmi Trimelamol (NSC-283162, Figure 13 ) is a synthetic analogue of pentamethylelamine and hexamethylmelamine which does not require in wivo metabolic activation (Rutty et al., 1986) and is active against B16 nmlanoma, colon 26, L1210 leukaemia, P388 leukaemia and other tumour models. The compound is soluble in water (-IOmgmP-'), DMA (-375mgml-'), propylene glycol (-15mgml-') and 95% ethanol (-45mgml-') . The stability of trimelamol was monitored by HPLC at 25C as a function of pH (pH values of 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12.5) , maximum stability was at pH 10-11 with a half-life >30 h. Decomposition was ignificntly faster at lower pH values and at pH 12.5. During decomposition an extremely insoluble dimer is formed and a precipitate starts to appear a few minutes after the compound dissolves. Additional stability and mhanistic studies related to trimelamol decomposition have been published recently (Jackson et al., 1991) . A lyophilised formulation was developed for clinical trial containing 250mg of trimelamol and 500mg of mannitol in a 100 ml vial. The formulation was reconstituted with 5% dextrose in water to a concentration of 4 mg ml-' and was used during phase I and limited phase H trials. As a single administration the maximum tolerated dose (MTD) was 2400mgm-2, while on a thrice-daily schedule it was 1000mg m2 (Judson et al., 1989) . The substantial doses required and the limited solubility of tlamol necessitated the administration of large volumes which was further complicated by the rapid precipitate formation. Because of these dificultis additional efforts have been directed at improving the trilamol formulation. Gibson et al. (1990) studied the solubility and stability in numerous vehicles including, DMSO, triacetin, polyvinylpyrrolidones, HPCD and polyethylene glycols of various molcular weight ranges. A new freeze-dried formulation was proposed consisting of a 50% aqueous PEG 3400 solution containing 30mgml-' of trimelamol. The freezedried cake reportedly was readily reconstituted with water and was stable (t/2 = 46.3 h) if not further diluted. However, the reported phase I dose of 800mg m2 (Judson et al., 1991) to a 2 m2 patient would require the administration of more than 25 g of PEG 3400. Additional toxicological studies may be required before initiation of clinical trials using this formulation. Other approaches based on the development of analogues of trimelamol are also under investigation. Figure 14) possible to obtain an i.v. LD1o in the mouse with the DMSO formulation, however an LD,O estimate was obtained by intraperitoneal (i.p.) administrtion of a suspension. Since it was known that temozolomide is ess toxi than mitozolomide and the recommended phase H dose for mitozolomide was 90-100 mg m 2, it was decided that 50 mg m 2 would be a safe starting dose for the temozolomide phase I trial. DMSO proved to be an unpopular choice of co-solvent with the nursing staff as the patients exhaled the metabolite dimethylsulpide, which had a characteristic unpleasant odour!! From previous experience, this became a problem when the total volume min reached 20 ml of DMSO. It was decided that a maximum 15 ml dose of DMSO would be administered i.v., limiting temozolomide dose escalation to 200 mg m2. At this dose patients were also given an oral formulation and the measured bioavailability was virtually 100% with a rapid adsorption. Further dose escalations were conducted with an oral formulation and there was no evidence of dose dependency in the pharmacokinetics. Following the determination of the MTD the administration schedule was switched to daily for five consecutive days, and it was on this schedule that activity aginst gliomas was evident (Stevens and Newlands, 1993) . The results from phase II trials against glioma and melanoma are currently under review, and it is hoped to commence further trials with a view to marketing in the near future. (Figure 16 ) had previously undergone phase I clinical trial (Rustin et al., 1992) , but it was decided to attempt to deliver total intravenous doses of up to 35 g. The drug's solubility in ethanol enabled this to be used as the vehicle with a final concentration of 600mgml-', which could be diluted before administration in 0.9% sodium chloride injection. The restraining factor with this formulation was the absolute volume of ethanol that could be infused per hour, which was limited by the rate of ethanol metabolism. If the infusion rate exceeded the metabolic rate it would result in the patients becoming intoxicated, which only happened on a few occasions. Hepatotoxicity was observed during the phase I trial but there was no evidence that this was ditly related to the formulation's ethanol content.
4-Hydroxyanisole 4-Hydroxyanisole
The examples above graphically illustrate the many and varied problems associated with the pharmaceutical development of new anti-cancer agents. In the majority of cases it was possible to develop adequate formulations that permitted trials to determine the agent's possible clinical utility. will also be required to minimise loss of these agents by adsorption during administration. During the past several years a large number of potential new compounds have been developed under the auspices of the JFWP. The JFWP has been the medium for an extensive exchange of pharmaceutical knowledge between CRC, EORTC and NCI and has facilitated the resolution of several formulation problems. It is essential that high quality standards are maintained and further sharpened with sufficient data acquired during development to permit acceptance by the regulatory authorities. Such a move would be another step in speeding the development process from putative agent to useful product. Much has been achieved; however much also remains to be done. Hopefully the JFWP will play an important role in this effort.
